Quotient Sciences, a drug development and manufacturing accelerator, announced on Monday that has named Dr Andrew Lewis as chief scientific officer, Kieron Hall as chief marketing officer, and Eric Bironneau as chief business officer.

The appointments are to assist in the company's strategic direction and growth.

Lewis has served at Quotient Sciences for eight years and worked in various scientific leadership positions, most recently as senior vice president, Pharmaceutical Development. He has worked as director of Novel Drug Delivery Technologies at Ipsen.

Hall has served with the company in various global commercial leadership positions for over 16 years, which includes chief commercial officer. He has worked as head of Business Development in Europe for Cyprotex (an Evotec company) prior to joining Quotient Sciences.

Bironneau has more than two decades of commercial leadership experience, which includes serving as vice president, Global Sales & Business Development at Axplora and Novasep.